{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.84","upperLimit":"50.60","value":"33.150"},{"groupId":"OG001","lowerLimit":"1.45","upperLimit":"49.81","value":"13.832"},{"groupId":"OG002","lowerLimit":"1.97","upperLimit":"33.15","value":"19.154"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"37"}],"units":"Participants"}],"description":"Duration of response as assessed by BIRC, is defined as the time interval from the date that the criteria are first met for CR/PR (whichever is first recorded) until the first date that progressive disease (PD) is objectively documented. CR is defined as disappearance of all extranodal target and non-target lesions. All pathological lymph nodes must have decreased to \\<10 mm in short axis for target lesions and all lymph nodes must be non-pathological in size (\\<10 mm short axis), normalization of tumor marker level for non-target lesions. PR is at least a 30 % decrease in the SLD of target lesions, taking as reference the baseline sum diameters. PD is SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest), the SLD must also demonstrate an absolute increase of at least 5 mm, and for non-target lesions, unequivocal progression of existing non-target lesions.","dispersionType":"Full Range","groups":[{"description":"Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).","id":"OG000","title":"Randomized Phase: Brigatinib 90 mg QD/180 QD"},{"description":"Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).","id":"OG001","title":"Randomized Phase: Crizotinib 250 mg BID"},{"description":"Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).","id":"OG002","title":"Crossover Phase: Brigatinib 90 mg QD/180 mg QD"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants randomized to each regimen regardless of whether they tested ALK+, or whether they received study drug or adhered to the assigned dose. Only responders were reported for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (Up to 56 months)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}